Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong & nbsp;

Peng, Qiaoli1,2,3,4; Zhou, Runhong1,2; Wang, Yuewen5; Zhao, Meiqing1,2; Liu, Na1,2; Li, Shuang1,2; Huang, Haode1,2; Yang, Dawei1,2; Au, Ka-Kit1,2; Wang, Hui3,4; Man, Kwan5; Yuen, Kwok-Yung1,2,6,7; Chen, Zhiwei1,2,3,4,6,7

2022-03-01

10.1016/j.ebiom.2022.103904

EBioMedicine   影响因子和分区

2352-3964

Background Nearly 4 billion doses of the BNT162b2-mRNA and CoronaVac-inactivated vaccines have been administrated globally, yet different vaccine-induced immunity against SARS-CoV-2 variants of concern (VOCs) remain incompletely investigated.& nbsp;Methods We compare the immunogenicity and durability of these two vaccines among fully vaccinated Hong Kong people.& nbsp;Findings Standard BNT162b2 and CoronaVac vaccinations were tolerated and induced neutralizing antibody (NAb) (100% and 85.7%) and spike-specific CD4 T cell responses (96.7% and 82.1%), respectively. The geometric mean NAb IC50 and median frequencies of reactive CD4 subsets were consistently lower among CoronaVac-vaccinees than BNT162b2-vaccinees. CoronaVac did not induce measurable levels of nucleocapsid protein-specific IFN-(+)(gamma) CD4+ T or IFN-(+)(gamma) CD8(+) T cells compared with unvaccinated. Against VOCs, NAb response rates and geometric mean IC50 titers against B.1.617.2 (Delta) and B.1.1.529 (Omicron) were significantly lower for CoronaVac (50%, 23.2 and 7.1%, < 20) than BNT162b2 (94.1%, 131 and 58.8%, 35.0), respectively. Three months after vaccinations, NAbs to VOCs dropped near to detection limit, along with waning memory T cell responses, mainly among CoronaVac-vaccinees.& nbsp;Interpretation Our results indicate that vaccinees especially CoronaVac-vaccinees with significantly reduced NAbs may probably face higher risk to pandemic VOCs breakthrough infection. Copyright (C)& nbsp;2022 The Authors. Published by Elsevier B.V.

SARS-CoV-2 mRNA vaccine Inactivated vaccine Cellular immune response Humoral immune response

SCI

英语

ESI高被引

通讯

Hong Kong Research Grants Council Collaborative Research Fund["C715620GF","C1134-20GF"] ; Wellcome Trust[P86433] ; National Program on Key Research Project of China["2020YFC0860600","2020YFA0707500","2020YFA0707504"] ; Shenzhen Science and Technology Program["JSGG20200225151410198","JCYJ20210324131610027"] ; Theme-Based Research Scheme[T11-706/18-N]

General & Internal Medicine ; Research & Experimental Medicine

Medicine, General & Internal ; Medicine, Research & Experimental

WOS:000794033100005

ELSEVIER

Web of Science

1.Univ Hong Kong, AIDS Inst, Li Ka Shing Fac Med, Hong Kong, Peoples R China
2.Univ Hong Kong, Dept Microbiol, Li Ka Shing Fac Med, Hong Kong, Peoples R China
3.Southern Univ Sci & Technol, Natl Clin Res Ctr Infect Dis, HKU AIDS Inst Shenzhen Res Lab, Peoples Hosp Shenzhen 3, Shenzhen, Guangdong, Peoples R China
4.Southern Univ Sci & Technol, Affiliated Hosp 2, Shenzhen, Guangdong, Peoples R China
5.Univ Hong Kong, Li Ka Shing Fac Med, Dept Surg, Hong Kong, Peoples R China
6.Univ Hong Kong, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China
7.Univ Hong Kong, Ctr Virol Vaccinol & Therapeut Ltd, Hong Kong, Peoples R China

Peng, Qiaoli,Zhou, Runhong,Wang, Yuewen,et al.

Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong & nbsp;

[J]. EBioMedicine,2022,77.

Peng, Qiaoli.,Zhou, Runhong.,Wang, Yuewen.,Zhao, Meiqing.,Liu, Na.,...&Chen, Zhiwei.(2022).

Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong & nbsp;

.EBioMedicine,77.

Peng, Qiaoli,et al."

Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong & nbsp;

".EBioMedicine 77(2022).